Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

• R. Colomer ^[8] ; I. Aranda-López ^[1] ; J. Albanell ^[2] ; T. García-Caballero ^[3] ; E. Ciruelos ^[9] ; M. Á. López-García ^[4] ; J. Cortés ^[5] ; F. Rojo ^[6] ; M. Martín ^[7] ; J. Palacios-Calvo ^[5]
  1. [1] Hospital General Universitario de Alicante

     Hospital General Universitario de Alicante

     Alicante, España

     
  2. [2] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  3. [3] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  4. [4] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  5. [5] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  6. [6] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  7. [7] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  8. [8] Hospital Universitario La Princesa, España
  9. [9] Hospital Universitario Doce de Octubre, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 7 (July 2018), 2018, págs. 815-826
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy. One of the four available genetic prognostic platforms (MammaPrint®, Oncotype DX®, Prosigna® or EndoPredict®) may be used in node-negative ER-positive patients to establish a prognostic category and decide with the patient whether adjuvant treatment may be limited to hormonal therapy. Newer technologies including next-generation sequencing, liquid biopsy, tumour-infiltrating lymphocytes or PD-1 determination are at this point investigational.